Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16713401 | 0.98 | DAO (0.43) | DAOCHRM3CHRM2CHRM1CES2 | |
| Fluoride SCHEMBL14940050 | 0.98 | DAO (0.43) | DAOCHRM3CHRM2CHRM1CES2 | |
| Bromomethane SCHEMBL5389919 | 0.94 | CHRM3 (0.41) | DAOCHRM3CHRM2CHRM1CES2 | |
| Iodomethane SCHEMBL6402613 | 0.94 | CHRM3 (0.41) | DAOCHRM3CHRM2CHRM1CES2 | |
| Fumaric Acid SCHEMBL17821282 | 0.91 | HCAR2 (0.49) | DAOCHRM3CHRM2CHRM1CES2 | |
| SCHEMBL73656 | 0.88 | CHRM3 (0.50) | DAOCHRM3CHRM2CHRM1CYP2C9 | |
| SCHEMBL5964331 | 0.88 | CHRM3 (0.50) | DAOCHRM3CHRM2CHRM1CYP2C9 | |
| SCHEMBL12633531 | 0.86 | CHRM3 (0.40) | DAOCHRM3CHRM2CHRM1CES2 | |
| SCHEMBL27661802 | 0.85 | SMN1; SMN2 (0.43) | CHRM3CHRM2CHRM1CYP2C9GAA | |
| SCHEMBL27681373 | 0.85 | CHRM3 (0.43) | CHRM3CHRM2CHRM1CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057683-A | Preparation method of tiotropium bromide intermediate | 鲁南制药集团股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| US-10632109-B2 | Tiotropium inhalation solution for nebulization | GLENMARK SPECIALTY S.A. (CH) | 2020-04-28 | — | — | US | claimed |
| US-20190231758-A1 | TIOTROPIUM INHALATION SOLUTION FOR NEBULIZATION | GLENMARK SPECIALTY S.A. (CH) | 2019-08-01 | — | — | US | claimed |
| WO-2018150347-A1 | COMPOUNDS WITH BETA-ADRENERGIC AGONIST AND ANTIMUSCARINIC ACTIVITY | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-08-23 | — | — | WO | claimed |
| US-9987260-B2 | Tiotropium inhalation solution for nebulization | GLENMARK SPECIALTY S.A. (CH) | 2018-06-05 | — | — | US | claimed |
| CN-108059632-A | A kind of preparation method of R-2,2- bis- (2- thienyls) -2- hydroxyacetic acid quinine -3- base esters | 扬州奥锐特药业有限公司 | 2018-05-22 | — | — | CN | claimed |
| EP-2961407-B1 | SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH 2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2018-04-11 | — | — | EP | claimed |
| WO-2018055642-A1 | A PROCESS FOR PREPARING TIOTROPIUM BROMIDE AND INTERMEDIATES THEREOF | GBR LABORATORIES PVT. LTD. (IN) | 2018-03-29 | — | — | WO | claimed |
| CN-105440030-B | A kind of choline m receptor antagonist aclidinium bromide and preparation method thereof | 东华大学 | 2017-08-01 | — | — | CN | claimed |
| CN-105348279-B | A kind of (2 thienyl) base esters of 2 hydroxyacetic acid quinine 3 of R 2,2 2 and its preparation and application | 东华大学 | 2017-06-06 | — | — | CN | claimed |
| US-20060047120-A1 | New method for preparing tiotropium salts | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-03-02 | — | — | US | claimed |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2006-01-05 | — | — | US | claimed |
| US-20050282875-A1 | Pyrrolidinium derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2005-12-22 | — | — | US | claimed |
| WO-2005090342-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL PRODESFARMA, SA (ES) | 2005-09-29 | — | — | WO | claimed |
| EP-1471919-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | claimed |
| EP-1497284-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | Almirall Prodesfarma AG (CH) | 2005-01-19 | — | — | EP | claimed |
| EP-1471919-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | claimed |
| EP-1156769-B1 | CARTRIDGE FOR A LIQUID | BOEHRINGER INGELHEIM INT (DE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003087094-A2 | PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS | ALMIRALL PRODESFARMA AG (CH) | 2003-10-23 | — | — | WO | claimed |
| WO-2003066063-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632109-B2 | Tiotropium inhalation solution for nebulization | IL5, CFTR, THOP1 | DAO 1960/4885CHRM3 18/4885CHRM2 65/4885 |
| US-20050282875-A1 | Pyrrolidinium derivatives | CHRM3, CHRM2, CHRM1 | DAO 3434/4885CHRM3 1/4885CHRM2 2/4885 |
| US-20190231758-A1 | TIOTROPIUM INHALATION SOLUTION FOR NEBULIZATION | IL5, CFTR, THOP1 | DAO 1960/4885CHRM3 18/4885CHRM2 65/4885 |
| US-20060002861-A1 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist | CYP17A1, HSD17B7, NR5A1 | DAO 3148/4885CHRM3 6/4885CHRM2 67/4885 |
| US-20060047120-A1 | New method for preparing tiotropium salts | NR5A1, THOP1, CYP21A2 | DAO 2738/4885CHRM3 141/4885CHRM2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.